BTC $67 359 -0.21%Gold $2 341 +0.55%USD/RUB 93.42 +0.43%EUR/RUB 101.77 +0.38%Brent $67.24 -0.81%MOEX 2 854 +1.02%BTC $67 359 -0.21%Gold $2 341 +0.55%USD/RUB 93.42 +0.43%EUR/RUB 101.77 +0.38%Brent $67.24 -0.81%MOEX 2 854 +1.02%BTC $67 359 -0.21%Gold $2 341 +0.55%USD/RUB 93.42 +0.43%EUR/RUB 101.77 +0.38%Brent $67.24 -0.81%MOEX 2 854 +1.02%
Work Life
TF
Korp&Co visual
Taylor Farms’ clash with FDA over parasite recall sparks PR backlash
#134801 · 21.07.2026
Work Life

Taylor Farms’ clash with FDA over parasite recall sparks PR backlash

When Taylor Farms announced that the FDA had issued an apology for a false-positive test result regarding its lettuce, the company aimed to clear its name. Instead, the move backfired, drawing a public rebuke from regulators and sharp criticism from communications experts who argue the company prioritized vindication over public safety.

The dispute centers on a cyclospora outbreak that has sickened thousands across the country. While Taylor Farms maintained that the FDA retracted a positive test result, the agency quickly countered on X, stating that the false positive did not alter the epidemiological data or the necessity of the voluntary recall. Federal officials urged consumers to continue avoiding the products, specifically those previously supplied to certain Taco Bell locations.

Crisis communications veterans suggest the company’s focus on the alleged apology undermined its credibility. Bradley Akubuiro, a former Boeing spokesperson, noted that framing the situation as a personal victory is premature while the investigation remains active. Other experts, including Kevin Donahue and Rod Hughes, highlighted that a more effective strategy would have centered on transparency and concrete corrective actions rather than antagonizing the federal body overseeing the recall. By centering its statement on an unconfirmed apology, Taylor Farms inadvertently invited intense scrutiny and shifted the narrative from consumer protection to a public dispute with its primary regulator.

Comments (0)

Leave a comment

No comments yet. Be the first!